CD200 and acute myeloid leukemia: Indeed, secondary‐type mutations were more frequently harbored in AML‐MRC‐M (21/25 patients, 84%) and AML‐MRC‐H (67/99 patients, 68%) compared to AML‐MRC‐C (52/142 patients, 37%) (p < 0.0001 and p < 0.0001, respectively).